Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

June 28, 2018

Study Completion Date

June 28, 2018

Conditions
Acute Respiratory Viral InfectionsInfluenza
Interventions
DRUG

XC221 100 mg

once daily during 3 days.

DRUG

XC221 200 mg

once daily during 3 days.

DRUG

Placebo

once daily during 3 days.

Trial Locations (11)

150007

Сlinical Hospital №3, Yaroslavl

190103

The Center for Prevention and Fight about AIDS and Infectious Diseases, Saint Petersburg

197110

The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation, Saint Petersburg

197376

Research Institute of Influenza, Saint Petersburg

197706

City Clinical Hospital №40 of Kurortny District, Saint Petersburg

344000

City Clinical Hospital №1 n.a. Semashko, Rostov-on-Don

350063

Kuban State Medical University, Krasnodar

390026

Ryazan State Medical University n.a. Pavlov, Ryazan

400131

Volgograd State Medical University, Clinical site - Infectious Regional Clinical Hospital № 1, Volgograd

426063

City Clinical Hospital №9, Izhevsk

430024

Mordovia State Medical University n.a. N.P.Ogarev, Clinical site - Republic Infectious Clinical Hospital, Saransk

All Listed Sponsors
lead

PHARMENTERPRISES LLC

INDUSTRY

NCT03455491 - Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections | Biotech Hunter | Biotech Hunter